TY - JOUR
T1 - Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors
AU - Bertolini, Francesco
PY - 2019/1/22
Y1 - 2019/1/22
N2 - Immune checkpoint inhibitors have shown unprecedented clinical activity in a variety of cancer types, but only in a fraction of patients. Promising in vivo synergies have been demonstrated between checkpoint inhibitors and other drugs and/or chemotherapy or radiotherapy, and effective models are now needed to select the best combinatorial regimen and disease setting.
AB - Immune checkpoint inhibitors have shown unprecedented clinical activity in a variety of cancer types, but only in a fraction of patients. Promising in vivo synergies have been demonstrated between checkpoint inhibitors and other drugs and/or chemotherapy or radiotherapy, and effective models are now needed to select the best combinatorial regimen and disease setting.
UR - http://www.scopus.com/inward/record.url?scp=85058212473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058212473&partnerID=8YFLogxK
U2 - 10.1038/s41416-018-0353-x
DO - 10.1038/s41416-018-0353-x
M3 - Editorial
C2 - 30538261
AN - SCOPUS:85058212473
VL - 120
SP - 139
EP - 140
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
ER -